Lenvatinib (lenvatinib) latest price in 2024

Lenvatinib (Lenvatinib) is a targeted drug that is widely used to treat certain types of cancer, particularly thyroid and liver cancer. As a multi-target inhibitor, it inhibits multiple receptor tyrosine kinase (RTK) pathways, such as vascular endothelial growth factor receptor (VEGFR), basic fibroblast growth Factor receptors (FGFR), PDGFR, KIT, etc., thereby inhibiting the growth and spread of tumors.

Lenvatinib (Lenvatinib) is currently on the market in China and has been included in medical insurance. Patients can purchase it domestically. Please consult the local hospital pharmacy for specific prices. There are original drugs and generic drugs abroad. The original drugs are mainly Japanese original drugs, and the price is more than 1,000 yuan. Generic drugs sold abroad are relatively cheap, such as the Lao and Bangladeshi versions, which cost around a few hundred yuan. The ingredients of original drugs and generic drugs are basically the same.

In the treatment of thyroid cancer,lenvatinib is often used in patients with advanced, refractory thyroid cancer, especially those who cannot be controlled with surgery or radiation therapy. By inhibiting vascular endothelial growth factor receptor (VEGFR) and other targets, it can inhibit tumor angiogenesis, thereby blocking the tumor's nutrient supply and slowing tumor growth. In the treatment of liver cancer, Lenvatinib also shows significant anti-tumor activity. By inhibiting the signaling pathways of multiple growth factor receptors, it inhibits the proliferation and metastasis of tumor cells and improves the survival of patients.

Although lenvatinib (lenvatinib) has shown significant effects in the treatment of cancer, it may also cause some adverse reactions, such as hypertension, hand-foot syndrome, proteinuria, rash, etc. Therefore, the patient's physical condition needs to be closely monitored during use and the dosage adjusted as needed.

In summary,lenvatinib as a targeted drug, has shown great potential in the treatment of thyroid cancer and liver cancer, providing a new treatment option for patients with refractory cancers. However, patients need to be closely monitored while receiving treatment and administered under the guidance of a physician to ensure safe and effective use of the drug.